Expression of COBLL1 encoding novel ROR1 binding partner is robust predictor of survival in chronic lymphocytic leukemia
نویسندگان
چکیده
Chronic lymphocytic leukemia is a disease with up-regulated expression of the transmembrane tyrosine-protein kinase ROR1, a member of the Wnt/planar cell polarity pathway. In this study, we identified COBLL1 as a novel interaction partner of ROR1. COBLL1 shows clear bimodal expression with high levels in chronic lymphocytic leukemia patients with mutated IGHV and approximately 30% of chronic lymphocytic leukemia patients with unmutated IGHV. In the remaining 70% of chronic lymphocytic leukemia patients with unmutated IGHV, COBLL1 expression is low. Importantly, chronic lymphocytic leukemia patients with unmutated IGHV and high COBLL1 have an unfavorable disease course with short overall survival and time to second treatment. COBLL1 serves as an independent molecular marker for overall survival in chronic lymphocytic leukemia patients with unmutated IGHV. In addition, chronic lymphocytic leukemia patients with unmutated IGHV and high COBLL1 show impaired motility and chemotaxis towards CCL19 and CXCL12 as well as enhanced B-cell receptor signaling pathway activation demonstrated by increased PLCγ2 and SYK phosphorylation after IgM stimulation. COBLL1 expression also changes during B-cell maturation in non-malignant secondary lymphoid tissue with a higher expression in germinal center B cells than naïve and memory B cells. Our data thus suggest COBLL1 involvement not only in chronic lymphocytic leukemia but also in B-cell development. In summary, we show that expression of COBLL1, encoding novel ROR1-binding partner, defines chronic lymphocytic leukemia subgroups with a distinct response to microenvironmental stimuli, and independently predicts survival of chronic lymphocytic leukemia with unmutated IGHV.
منابع مشابه
Expression of ROR1 in Patients with Renal Cancer-A Potential Diagnostic Marker
Background: The ectopic expression of receptor tyrosine kinase Ror1 has been reported in patients with hematological malignancies such as chronic lymphocytic leukemia and acute lymphoblastic leukemia. Here we report, for the first time, expression of ROR1 gene in both tumor tissues and peripheral blood mononuclear cells (PBMC) from patients with renal cancer (RC). Methods: In the current study,...
متن کاملDown-regulation of miR-193b-3p and miR-376a-3p in Chronic Lymphocytic Leukemia
Background: Chronic lymphocytic leukemia (CLL) is the most common adult human leukemia. Studies revealed that microRNAs (miRNAs) can function as oncogenes or tumor suppressors in CLL and that the expression of miRNAs, such as miR-193b-3p and miR-376a-3p change in several diseases. We aimed to elucidate the changes in miR-193b-3p and miR-376a-3p expression in CLL and determine their potential as...
متن کاملEffect of curcumin on growth inhibition and gene expression reduction in chronic lymphocytic leukemia cells (CLL-CII)
Introduction: Chronic lymphocytic leukemia (CLL) is the most frequent leukemia in adults living in Western countries. with a diverse clinical course that due to life expectancy less than two years between patients finding ,new therapeutic strategies is essential for it. Curcumin as the biologic active of turmeric, has many biological properties such as anti-inflammatory, anti-oxidant, anti-diab...
متن کاملExpression of miR-485-3p and its Target FOXD3 in Chronic Lymphocytic Leukemia
Background and Aims: Previous investigations have revealed that microRNAs (miRNAs) can function as oncogenes or tumor suppressors in chronic lymphocytic leukemia (CLL) and that the expression of miRNAs, such as miR-485-3p changes in several illnesses. This study was designed to determine the expression level of miR-485-3p and its target FOXD3 in CLL patients and controls to identify if this miR...
متن کاملTargeting malignant B cells with an immunotoxin against ROR1
The selective cell surface expression of receptor tyrosine kinase-like orphan receptor 1 (ROR1) in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) has made ROR1 a novel and promising target for therapeutic monoclonal antibodies (mAbs). Four mouse mAbs generated by hybridoma technology exhibited specific binding to human ROR1. Epitope mapping studies showed that two mAbs (2A2 a...
متن کامل